News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
685,521 Results
Type
Article (39044)
Company Profile (279)
Press Release (646198)
Section
Business (203861)
Career Advice (1990)
Deals (35362)
Drug Delivery (85)
Drug Development (80799)
Employer Resources (168)
FDA (16086)
Job Trends (14804)
News (344539)
Policy (32436)
Tag
Academia (2530)
Alliances (49082)
Alzheimer's disease (1228)
Approvals (16018)
Artificial intelligence (130)
Bankruptcy (352)
Best Places to Work (11534)
Biotechnology (200)
Breast cancer (120)
Cancer (1080)
Cardiovascular disease (97)
Career advice (1660)
Cell therapy (232)
Clinical research (64237)
Collaboration (386)
Compensation (197)
COVID-19 (2530)
C-suite (94)
Data (1119)
Diabetes (152)
Diagnostics (6138)
Earnings (84816)
Employer resources (146)
Events (109456)
Executive appointments (308)
FDA (16619)
Funding (347)
Gene therapy (176)
GLP-1 (575)
Government (4324)
Healthcare (18668)
Infectious disease (2614)
Inflammatory bowel disease (106)
Interviews (308)
IPO (16296)
Job creations (3623)
Job search strategy (1417)
Layoffs (412)
Legal (7853)
Lung cancer (170)
Manufacturing (176)
Medical device (13174)
Medtech (13179)
Mergers & acquisitions (19138)
Metabolic disorders (400)
Neuroscience (1503)
NextGen Class of 2024 (6499)
Non-profit (4464)
Northern California (1475)
Obesity (230)
Opinion (179)
Patents (101)
People (56263)
Phase I (19950)
Phase II (28297)
Phase III (21095)
Pipeline (454)
Postmarket research (2553)
Preclinical (8488)
Radiopharmaceuticals (236)
Rare diseases (218)
Real estate (5890)
Regulatory (21517)
Research institute (2308)
Resumes & cover letters (349)
Southern California (1297)
Startups (3561)
United States (13407)
Vaccines (548)
Weight loss (167)
Date
Today (139)
Last 7 days (824)
Last 30 days (3768)
Last 365 days (35599)
2024 (32628)
2023 (40074)
2022 (51173)
2021 (55712)
2020 (54087)
2019 (46541)
2018 (35019)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (192)
Asia (37115)
Australia (6057)
California (3309)
Canada (1286)
China (247)
Colorado (144)
Connecticut (151)
Europe (79495)
Florida (457)
Georgia (116)
Illinois (340)
Indiana (196)
Kansas (96)
Maryland (574)
Massachusetts (2596)
Michigan (157)
Minnesota (271)
New Jersey (950)
New York (952)
North Carolina (698)
Northern California (1475)
Ohio (138)
Pennsylvania (841)
South America (1091)
Southern California (1297)
Texas (460)
Utah (90)
Washington State (358)
685,521 Results for "cerapedics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cerapedics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Cerapedics Inc. today announced that Valeska Schroeder , Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference.
January 5, 2024
·
1 min read
Press Releases
Cerapedics’ i-FACTOR P-15 Peptide Enhanced Bone Graft, a Trusted Choice in Bone Graft Solutions, Now Approved for Expanded Indications for Use
September 24, 2024
·
3 min read
Policy
Cerapedics Files Final Module of the PMA Application for FDA Approval of a new P-15 Peptide Enhanced Bone Graft for Lumbar Spine Fusion
Cerapedics Inc., a commercial-stage orthopedics company dedicated to redefining the standard of care for bone repair, announced that it has filed the final module in the Pre-Market Approval application with the U.S. Food and Drug Administration for its investigational P-15 Peptide Enhanced Bone Graft.
January 4, 2024
·
3 min read
Business
Cerapedics™ Announces Expansion of Headquarters to Support Growth of its Bone Graft Products
Cerapedics Inc. announced it is expanding its headquarters in the Denver metro area to support the growth of its products, which include the U.S. Food and Drug Administration -approved i-FACTOR® bone graft for cervical spinal fusion and its next-generation product currently being evaluated for lumbar spinal fusion.
July 19, 2023
·
2 min read
BioMidwest
Cerapedics Reinforces Commitment to Level 1 Evidence with Long-Term Results from Six-Year Pivotal IDE Cervical Study Demonstrating 98.6% Spine Fusion Rates in Patients Treated With i-FACTOR®
Cerapedics Inc., a commercial-stage orthopedics company dedicated to redefining the standard of care for bone repair, announced long-term follow-up data from its pivotal IDE study of i-FACTOR Peptide-Enhanced Bone Graft.
October 17, 2023
·
4 min read
Business
Cerapedics Appoints Valeska Schroeder Chairman and Chief Executive Officer
Cerapedics Inc., a commercial-stage ortho-biologics company dedicated to enhancing the science of bone repair, announced today that Valeska Schroeder has been appointed Chief Executive Officer effective November 1st, while continuing as Chairman of the Company’s Board of Directors.
October 10, 2022
·
2 min read
Press Releases
ABS Bio, Inc. announces strategic investment by 3 Boomerang Capital
◆Investment to support services growth. ◆Industry veterans join board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.
November 14, 2024
·
1 min read
Cerapedics Completes Enrollment of Pivotal U.S. FDA IDE Study for its P-15L Bone Graft
Cerapedics Inc. announced today the completion of enrollment of the ASPIRE study, a pivotal U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) study.
February 24, 2022
·
3 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Press Releases
Boston Scientific Closes Acquisition of Axonics, Inc.
November 15, 2024
·
5 min read
1 of 68,553
Next
